Heart Disease Trial, Recruiting NCT05486000 Sponsor: Morningside (Nantong) Medical Co.,Ltd Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT05486000
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older
  • People with chronic left-sided heart failure who are still experiencing symptoms despite being on stable, guideline-recommended heart failure medications for at least 1 month
  • People who have been hospitalised for heart failure in the past 12 months, and whose blood test results show elevated heart failure markers (BNP or NT-proBNP) within the past 6 months — the specific levels required depend on whether the person has a normal heart rhythm or atrial fibrillation (confirm with trial site)
  • People whose heart pressure measurements, taken during a cardiac catheterisation procedure, show a resting lung capillary wedge pressure or left atrial pressure of 15 mmHg or higher, with a specific pressure difference between the lung and right heart chambers also met (confirm with trial site)
  • People with a heart function classification of Grade II, III, or IV on the standard NYHA scale — meaning symptoms ranging from mild to severe
  • People (or their legal guardian) who are able to understand the purpose of the study, agree to take part voluntarily, and sign a written consent form, and who are able to attend follow-up appointments

Who may not be able to join:

  • People with a major heart valve disease or severe blocked heart arteries that currently require surgical treatment, or a heart condition that currently requires a pacemaker
  • People with pulmonary hypertension where the resistance in the lung blood vessels exceeds 4 Wood Units
  • People who have had a heart attack or heart surgery within the past three months
  • People with an active heart infection (infective endocarditis), or where imaging has found blood clots or abnormal growths inside the heart
  • People whose heart or blood vessel anatomy makes the procedure technically impossible or medically unsuitable
  • People whose life expectancy is estimated to be less than 12 months
  • People who have had a stroke, a mini-stroke (transient ischaemic attack), a blood clot in a deep vein, or a blood clot in the lungs within the past 6 months
  • Women who are pregnant or breastfeeding, or people who are planning to have a child within the next year
  • People who are considered unlikely to follow the study requirements or complete the full study as needed

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: yan wang, dean, Xiamen Cardiovascular Hospital, Xiamen University

Phone: +8613774401524

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Morningside (Nantong) Medical Co.,Ltd
Registry
ClinicalTrials.gov
Start date
1 August 2022
Est. completion
1 October 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The clinical treatment success rate was 12 months after operation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov